N-aryl-2-(2-arylaminopyrimidin-4-yl)pyrrol-4-carboxamide derivatives as MPS1 kinase inhibitors
AssigneeNerviano Medical Sciences S.R.L.
InventorsMarina Caldarelli, Stefano Adele Nuvoloni, Francesca Quartieri
Life of this patent
Estimating the term…
Abstract
The present invention relates to substituted pyrrolyl-pyrimidines which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity, in particular MPS1. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing such these compounds or the pharmaceutical compositions containing them.
Claims13
A compound of the formula (I):
- wherein
- R1 is a phenyl group;
- R2 is hydrogen atom or straight or branched C1-C6 alkyl;
- R3 is an aryl group;
- R4 is hydrogen atom;
- R5 and R7 are each independently hydrogen or halogen atom;
- R6 is hydrogen, halogen atom or a C1-C6 alkyl group;
- wherein the groups phenyl, aryl and straight or branched C1-C6 alkyl may be optionally substituted,
- provided that the compound 1-methyl-5-{2-[4-(1-methyl-piperidin-4-ylcarbamoyl)-2-trifluoromethoxy-phenylamino]-pyrimidin-4-yl}-1H-pyrrole-3-carboxylic acid o-tolylamide is excluded;
- and stereoisomers, tautomers, hydrates, solvates, N-oxides and pharmaceutically acceptable salts thereof.
A product comprising a compound of formula (I) as defined in claim 1 or a pharmaceutical composition thereof as defined in claim 11, and one or more chemotherapeutic agents, as a combined preparation for simultaneous, separate or sequential use in anticancer therapy.
Dependencies are inferred from the claim text.